跳至主要内容
临床试验/EUCTR2021-003331-28-ES
EUCTR2021-003331-28-ES进行中(未招募)1 期

Randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy and safety of the COMIRNATY vaccine (COVID-19 mRNA vaccine, Pfizer-BioNTech) in people with long COVID

Felix Gutierrez Rodero0 个研究点目标入组 776 人开始时间: 2021年6月21日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
入组人数
776

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Adults (=18 years) admitted for COVID-19 who continue with moderate or severe symptoms collected in the COVID-19 Symptom Questionnaire” three months after hospital discharge and who sign the informed consent
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 776
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Patients who have received any dose of any of the COVID-19 vaccines.
  • -Contraindication for the COMIRNATY vaccine according to the technical data sheet.
  • -Women who are pregnant or intend to become pregnant during the next three months after the administration of the vaccine.

研究者

发起方
Felix Gutierrez Rodero

相似试验